VERTEX PHARMACEUTICALS INC / MA

Resolved promises

Credibility timeline

Resolved promises

Guidance by basis

0 of 1 guidance figures that were graded or dropped for basis could not be graded on the same basis (0%). Guidance marked “not judged” is in neither number.

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (19)

We show what was said — with its source filing — but never score it. The line under each statement says why.

1. revenue guidance fy · Nov 4, 2024
   Raising full-year product revenue guidance to $10.8 billion to $10.9 billion
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
2. revenue guidance fy · Aug 1, 2024
   Vertex today raised its full year product revenue guidance from $10.55-$10.75 billion to $10.65-$10.85 billion.
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
3. revenue guidance fy · May 6, 2024
   product revenue guidance of $10.55 to $10.75 billion
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
4. revenue guidance fy · Feb 5, 2024
   Company provides full year 2024 product revenue guidance of $10.55 to $10.75 billion
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
5. revenue guidance fy · Nov 6, 2023
   Vertex today raised its full year 2023 CF product revenue guidance to approximately $9.85 billion.
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
6. revenue guidance fy · Aug 1, 2023
   Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
7. revenue guidance fy · May 1, 2023
   product revenue guidance of $9.55 to $9.7 billion
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
8. revenue guidance fy · Feb 7, 2023
   Vertex’s combined Non-GAAP R&D, Acquired IPR&D and SG&A expense guidance includes expectations for continued investment in our multiple mid- and late-stage clinical development programs, commercial and manufacturing capabilities, and approximately $300 million of upfront and milestone payments from existing collaborations and our anticipated transaction with Entrada Therapeutics. Vertex’s guidance is summarized below: FY 2023 CF product revenues $9.55 to $9.7 billion
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
9. revenue guidance fy · Oct 27, 2022
   Product revenues $8.8 to $8.9 billion
   Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
10. revenue guidance fy · Aug 4, 2022
    Vertex is raising its full year 2022 product revenue guidance to $8.6 to $8.8 billion.
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
11. revenue guidance fy · May 5, 2022
    Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
12. revenue guidance fy · Jan 26, 2022
    Product revenues $8.4 to $8.6 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
13. revenue guidance fy · Nov 2, 2021
    Product revenues $7.4 to 7.5 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
14. revenue guidance fy · Jul 29, 2021
    Product revenues $7.2 to 7.4 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
15. revenue guidance fy · Apr 29, 2021
    Product revenues Unchanged $6.7 to 6.9 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
16. revenue guidance fy · Feb 1, 2021
    Product revenues $6.7 to 6.9 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
17. revenue guidance fy · Oct 29, 2020
    now expects 2020 product revenues of $6.0 to $6.2 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
18. revenue guidance fy · Jul 30, 2020
    now expects 2020 CF revenues of $5.7 to $5.9 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
19. revenue guidance fy · Jul 25, 2018
    Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗

Open promises (1) · 5 superseded

Credibility timeline